Centogene NV (CNTG - Research Report) received a Buy rating and a $2.50 price target from H.C. Wainwright analyst Yi Chen today. The company's shares closed yesterday at $0.75.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -29.6% and a 22.28% success rate on recommended stocks. Currently, the analyst consensus on Centogene NV is a Moderate Buy with an average price target of $2.50.See the top stocks recommended by analysts >>Based on Centogene NV's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10.
https://www.tipranks.com/news/blurbs/centogene-nv-cntg-initiated-with-a-buy-at-h-c-wainwright?utm_source=advfn.com&utm_medium=referral